Dihydromyricetin, almost always called DHM, is a flavonoid extracted from the Japanese raisin tree (Hovenia dulcis) and Chinese vine tea (Ampelopsis grossedentata). Most people use it to take the edge off drinking. A dose before or after alcohol tends to leave you sharper that night and less wrecked the next morning. It's the active ingredient in almost every modern hangover supplement on the market.
DHM helps with faster acetaldehyde clearance, has anti-inflammatory effects and reduce the liver damage but also reduces the buzz (GABA-A antagonism).
DHM seems to blunt some of alcohol's effects on the brain, push the liver to clear alcohol and its toxic byproduct acetaldehyde faster, and reduce the inflammation that drives a lot of hangover symptoms. It won't make heavy drinking safe and it won't stop you from getting drunk if you drink hard enough. What it does, in the people it works for, is shift the experience: you feel the alcohol a bit less acutely, recover a bit faster, and the next morning feels less like a write-off. Separately, there's reasonable human evidence that DHM improves liver function and metabolic markers in people with fatty liver, so it has a second use case for anyone with elevated liver enzymes or NAFLD on bloodwork.
Deep-dive
Mechanism on the brain. Alcohol's acute effects, the sedation, slurring, impaired coordination, and disinhibition, come largely from potentiating GABA-A receptors, the brain's main inhibitory channels. DHM appears to sit at the same receptor family but acts as a competitive antagonist at the benzodiazepine binding site, blunting alcohol's potentiation without producing sedation on its own. The foundational rat work published in the Journal of Neuroscience in 2012 showed that DHM at 1 mg/kg counteracted acute alcohol intoxication (measured by loss of righting reflex), reduced anxiety and seizure susceptibility in withdrawal, and cut voluntary alcohol consumption in an intermittent access paradigm. Flumazenil, a benzodiazepine site antagonist, blocked all of DHM's effects, confirming the mechanism. Follow-up work in α5β3γ2 GABA-A receptors expressed in Xenopus oocytes showed DHM at 10 µM potentiated GABAergic activity by 43.2% on its own, but interestingly, its primary methylated metabolite negatively modulated the same receptor, suggesting the in vivo effect is more complex than a single binding interaction.
Mechanism on the liver. DHM also accelerates alcohol metabolism. In a mouse forced-drinking model, DHM supplementation upregulated alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), the two enzymes that convert ethanol to acetaldehyde and then acetaldehyde to acetate. It also reduced ethanol-induced fatty liver, lowered hepatic triglycerides, and suppressed inflammatory cytokine activation in Kupffer cells. The faster ALDH activity matters because acetaldehyde is the toxic intermediate responsible for much of the next-day misery and most of alcohol's long-term cancer risk. Speeding its clearance is the same principle behind why people of East Asian descent with efficient ALDH2 variants tolerate alcohol better than those with the deficient variant.
Human alcohol data. This is where things get thinner. Most of the strong mechanistic work is rodent, and the human trials so far have used Hovenia dulcis fruit extract (HDE) rather than purified DHM. A 2017 Korean crossover trial in 26 young men with the ALDH2 1/2 heterozygous variant (the slow-acetaldehyde-clearing genotype common in East Asians) gave 2460 mg of standardised HDE with 50 g of alcohol. Blood alcohol and acetaldehyde peaks didn't differ from placebo, but hangover symptom scores declined significantly faster, and inflammatory markers (IL-6, IL-10, AST) were lower. A 2024 follow-up trial with 30 subjects using HDE-containing beverages found lower blood alcohol at 0.5 and 6 hours post-drinking. The Verster group's 2021 ECNP presentation on DHM specifically reported reduced gastrointestinal hangover symptoms but the data hasn't been published in full. The honest summary: there's a coherent mechanistic story and several human trials showing benefit on symptoms or markers, but no large RCT of purified DHM in a Western population yet exists, and the field has been openly criticised for the gap between marketing claims and direct hangover-severity evidence.
Bioavailability is the central problem. Like most flavonoids, DHM is poorly absorbed orally. Rat pharmacokinetic work puts absolute oral bioavailability at 4.02%, with a plasma half-life around 3.7 hours. The mouse study cited above found that oral DHM produced 23.8-fold lower serum exposure in males and 7.2-fold lower in females compared to intraperitoneal injection at the same dose, and brain levels dropped below detection within 45 minutes. This is the most important caveat for interpreting all the rodent work: the mechanism may be real, but the doses people take orally produce a small fraction of the brain exposure used in the foundational studies. It also means timing matters more than it would for a well-absorbed drug. Take it 30 to 60 minutes before drinking to get peak levels onboard while alcohol is being absorbed.
NAFLD and metabolic effects. This is actually the strongest human evidence for DHM. A 2015 double-blind RCT in Pharmacological Research randomised 60 adults with NAFLD to 300 mg of DHM twice daily or placebo for 3 months. The DHM group showed significant reductions in ALT, AST, GGT, fasting glucose, LDL cholesterol, apolipoprotein B, HOMA-IR (insulin resistance), TNF-α, cytokeratin-18 (a hepatocyte damage marker), and FGF-21, alongside an increase in serum adiponectin. The effect size was meaningful: a roughly 30% reduction in ALT. Mechanistic follow-up work traced this to DHM activating SIRT3 signalling, restoring mitochondrial respiratory capacity, and reducing hepatic oxidative stress. If you have fatty liver on imaging or persistently elevated liver enzymes, this is the more defensible long-term use case for DHM than hangover prevention.
Withdrawal and dependence. The rat work suggests DHM blunts alcohol withdrawal anxiety and seizure susceptibility, and reduces voluntary alcohol intake over weeks. This has led to ongoing interest in DHM as a potential alcohol use disorder treatment, though no human RCTs in AUD have completed. The practical implication for casual users: DHM's GABA-A activity doesn't appear to produce tolerance, sedation, or withdrawal of its own across the dose ranges studied, which is consistent with it acting as an antagonist rather than a positive modulator at the benzodiazepine site. Don't read this as a guarantee. Long-term human data is thin.
Women. This is where the evidence gets genuinely thin. Almost all the foundational rodent work used male animals, and the bioavailability study cited above found female mice had roughly one-third the oral DHM exposure of males at the same weight-adjusted dose, suggesting sex differences in absorption or first-pass metabolism that haven't been worked out. The 2017 HDE hangover trial used men only. The 2015 NAFLD trial included women but didn't report sex-stratified outcomes. Practically, women clear DHM faster and likely need to either dose higher or split doses across a drinking session to maintain blood levels. The other relevant factor is that women reach higher blood alcohol concentrations than men from the same dose due to lower total body water and reduced gastric ADH, so the practical hangover-prevention case is at least as strong, but the dose-response hasn't been mapped in women. Skip it in pregnancy and breastfeeding, no human safety data.
Limitations of the evidence. The honest picture: foundational rodent mechanism work is strong, the NAFLD human trial is real and replicated mechanistically, but the hangover claims rest on a small number of human trials using whole-plant extracts (not pure DHM), with mostly East Asian male subjects, sometimes selected for ALDH2 deficiency, often industry-funded, and with conference-only presentation rather than full publication for some of the key results. DHM probably works for hangovers in some people, but the effect size in the average Western drinker without ALDH2 polymorphisms is genuinely unclear. The strongest stance is: it's cheap, it's safe, the mechanism is plausible, and the worst case is you wasted some money.
Dosage:
- For hangover prevention: 300-600 mg taken 30-60 minutes before your first drink. Split-dose for longer sessions: half before, half partway through, or half before and half before bed with a glass of water. Women may need to lean toward the higher end of the range or split-dose more aggressively given faster clearance
- For active hangover (already drunk or the next morning): 300-600 mg with water and food. Effect is more modest than prevention because the peak alcohol and acetaldehyde exposure has already happened, but the anti-inflammatory and ALDH-supporting effects can still help recovery
- For NAFLD or elevated liver enzymes: 300 mg twice daily for at least 3 months, the protocol used in the Chen 2015 RCT. This is a daily regimen, not situational. Recheck liver enzymes at 3 months
- Timing: Bioavailability is poor and the half-life is short (around 3-4 hours), so timing matters more than for most supplements. Take it close to the alcohol exposure, not hours before. Taking it with a fatty meal may slow absorption slightly but also extend the window, which can be useful for long drinking sessions
- Forms: Standardised DHM extract powder or capsules (look for 98%+ purity from a reputable source) is the cleanest option. Whole-plant Hovenia dulcis fruit extract is what most of the human trials actually used, contains other flavonoids and quercetin that may contribute to the effect, and works fine if that's what's available. Avoid stacks that include curcumin, daidzein, or resveratrol with DHM, a 2020 study showed those combinations diminished DHM's GABA-A activity in vitro, possibly through competitive binding
- Stacks: Pairs well with Glutathione or its precursor NAC for the acetaldehyde-clearing side, since glutathione is the cofactor for the next step in alcohol metabolism. Pairs with electrolytes and water for the hangover use case, since alcohol's diuretic effect is independent of DHM's mechanism. Do not stack with
Benzodiazepines (alprazolam, clonazepam, diazepam, lorazepam), Z-drugs, or other GABA-A agonists, the interaction is theoretically antagonistic and clinically untested in humans
- DHM is not a license to drink more. The dose-response on liver damage, brain volume loss, blood pressure, and cancer risk from alcohol is linear with no threshold, and DHM doesn't change any of that. It can take the edge off the acute experience and the next-morning hangover, nothing more
Here's what you can expect:
If DHM works for you, the most common subjective effects are: you feel the alcohol slightly less, you sober up a bit faster (the second half of a drinking session feels less impaired than usual), and the next morning is noticeably less rough. Headache, nausea, and brain fog are typically what improve most. The effect is real but modest, somewhere in the range of one or two fewer drinks' worth of hangover, not a complete eraser. People expecting to feel completely fine after a hard night will be disappointed.
If DHM doesn't work for you, you'll notice nothing. Response varies and not everyone gets the effect, possibly due to absorption differences, ALDH genetics, or the specific symptoms that drive your hangovers (DHM helps with the inflammatory and GABA-rebound components more than dehydration or sleep disruption).
For NAFLD, you won't feel anything subjectively in the short term. What you'll see, if it's working, is liver enzymes (ALT, AST, GGT) drop on bloodwork at 3 months along with improvements in fasting glucose, LDL, and insulin resistance markers.
Side effects & risks:
- GI discomfort is the most reported side effect: mild nausea, dry mouth, or stomach upset, especially on an empty stomach. Resolves by taking with food or water. Rare
- Sedation and CNS interactions: DHM acts at GABA-A receptors. While it appears to be an antagonist of alcohol's effects rather than a sedative on its own, the interaction with benzodiazepines, Z-drugs, phenibut, kava, baclofen, and other GABAergic compounds is theoretically complex and clinically uncharacterised. Avoid stacking until more is known
- No evidence of hepatotoxicity. The NIH LiverTox database reports no documented cases of DHM-associated serum enzyme elevations or clinically apparent liver injury. Acute toxicity studies in rodents have failed to find a lethal dose up to 10-22 g/kg, suggesting an extremely wide safety margin
- Drug-metabolising enzyme interactions: DHM may modulate CYP450 enzymes in vitro, which could theoretically alter the metabolism of medications cleared by the same pathways. Clinically significant interactions haven't been documented, but caution if you're on narrow-therapeutic-index drugs cleared by CYP3A4 or CYP2E1
- Pregnancy and breastfeeding: Skip it. No human safety data exists in either population
- Hypoglycaemia caution: DHM lowers fasting glucose in NAFLD patients. If you're on insulin, sulfonylureas, or other glucose-lowering medications and use DHM chronically, monitor for hypoglycaemia
- Children: No data. Adult use only
- Long-term safety data is limited. The longest controlled human trial ran 3 months. Multi-year daily use hasn't been studied. For situational hangover use this matters less. For chronic NAFLD-protocol use, recheck bloodwork periodically
- The big caveat: DHM doesn't change the dose-dependent cancer, liver disease, brain volume, and cardiovascular risk of alcohol itself. Treating it as a hangover band-aid is reasonable; treating it as alcohol protection is not
Blood markers
ALT, AST, GGT, baseline if you're considering DHM specifically for liver protection or you drink regularly. These are the markers most likely to move on a daily DHM regimen. Recheck at 3 months. GGT is the most alcohol-sensitive of the three and tends to respond first.
Fasting glucose and HbA1c, baseline if running the NAFLD protocol (300 mg twice daily for 3+ months) or if you have insulin resistance. DHM consistently improves both in the human trial data, which is useful if you're insulin-resistant and a relevant interaction risk if you're on glucose-lowering medication.
Lipid panel (LDL, ApoB, triglycerides), baseline if running daily, since DHM lowered LDL and ApoB meaningfully in the NAFLD trial. Recheck at 3 months.
MCV on a standard CBC, baseline if you're using DHM because you drink regularly and want to track whether your average exposure is actually changing. MCV is one of the more sensitive markers of sustained alcohol intake and reflects bone marrow exposure over months.
For occasional hangover-prevention use (a few times a month before social drinking), no specific bloodwork is needed. Baseline testing matters for anyone running daily protocols beyond a month, anyone using DHM as part of liver-protection stack, and anyone whose drinking is heavy enough that you'd want liver markers tracked regardless.
Sold as a dietary supplement in most countries without prescription.
Made with Bullet